Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 786 | 442 | 450 | 94.5 | — |
| Depreciation and amortization | 278 | 249 | 220 | 184 | — |
| Capital expenditure | -332 | -441 | -391 | -700 | — |
| Investing cash flow | -156 | -302 | -383 | -540 | — |
| Financing cash flow | -292 | -251 | 328 | 624 | — |
| Dividends paid | -333 | -422 | -42.6 | -247 | — |
| Debt issued | 1,050 | 1,378 | 887 | 1,985 | — |
| Debt repaid | -1,011 | -1,292 | -1,175 | -1,128 | — |
| Effect of exchange rates | -6.9 | 4.9 | -1.5 | 16.9 | — |
| Net change in cash | 338 | -110 | 394 | 179 | — |
| Free cash flow | 454 | 1.4 | 58.6 | -606 | — |